NCT06939036 - Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Small Cell Lung Cancer Extensive StageMerkel Cell Carcinoma

Interventions

DRUG

225Ac-SSO110 + SoC

Dose Level -2-7

DRUG

Atezolizumab

Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)

DRUG

Durvalumab

Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)

DRUG

Avelumab

Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

DRUG

Pembrolizumab

Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

DRUG

Retifanlimab

Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)

Trial Locations (5)

RECRUITING

UPMC, Pittsburgh

RECRUITING

United Theranostics, Glen Burnie

RECRUITING

Virginia Cancer Specialists, PC, Fairfax

RECRUITING

Biogenix Molecular, Miami

RECRUITING

University of Louisville Health-Brown Cancer Center, Louisville